Skip to Content

ExoQuick CG

https://www.metadatabase.org/web/image/product.template/50502/image_1920?unique=6d94a52
ExoQuick® Clinical-Grade is a specialized formulation manufactured for clinical and translational exosome purification workflows, produced in compliance with FDA 21 CFR Part 820 quality system regulations. This version is designed to support researchers and developers working toward clinical applications, regulatory submissions, and GMP-aligned manufacturing pipelines.

1,196.00 € 1196.0 EUR 1,196.00 €

1,196.00 €

Not Available For Sale

(0.00 € / Units)

This combination does not exist.

Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days

How It Works ?

Exosome Size Distribution and Yields Using ExoQuick-CG

Figure 1. ExoQuick-CG efficiently isolates exosomes from conditioned cell culture media.

3.3 mL of ExoQuick-CG was added to 10 mL of conditioned media collected from human HT1080 lung sarcoma cells or mouse JAWS II dendritic cells cultured in Exo-FBS (exosome-depleted FBS medium supplement; Cat. No. EXO-FBS-50A-1). Samples were incubated overnight at 4 °C to allow exosome precipitation. Following centrifugation, exosome pellets were resuspended in 0.5 mL PBS and analyzed using a NanoSight LM10 instrument for visualization and particle assessment.

Exosome CD63 Western Blot Validation Studies

Figure 2. Western blot confirmation of exosome marker CD63 in ExoQuick-CG–isolated samples.

Approximately 10–50 µg of exosomal protein, obtained from the NanoSight analyses shown in Figure 1, was resolved by denaturing SDS-PAGE and analyzed by Western blotting. The exosome-specific marker CD63 was detected using SBI’s rabbit anti-CD63 primary antibody and an HRP-conjugated goat anti-rabbit secondary antibody (Cat. No. EXOAB-CD63A-1), confirming successful isolation of CD63-positive exosomes.